Sweden
· Delayed Price · Currency is SEK IRLAB Therapeutics AB Statistics
Total Valuation
IRLAB Therapeutics AB has a market cap or net worth of SEK 746.91 million. The enterprise value is 703.86 million.
| Market Cap | 746.91M |
| Enterprise Value | 703.86M |
Important Dates
The next estimated earnings date is Wednesday, October 30, 2024.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
IRLAB Therapeutics AB has 51.87 million shares outstanding. The number of shares has increased by 0.13% in one year.
| Shares Outstanding | 51.87M |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | +3.32% |
| Owned by Insiders (%) | 22.28% |
| Owned by Institutions (%) | 37.11% |
| Float | 33.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.96 |
| PB Ratio | 10.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.89 |
| EV / Sales | 16.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 79.25.
| Current Ratio | 1.15 |
| Quick Ratio | 1.15 |
| Debt / Equity | 79.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.55 |
Financial Efficiency
Return on equity (ROE) is -93.30% and return on invested capital (ROIC) is -51.45%.
| Return on Equity (ROE) | -93.30% |
| Return on Assets (ROA) | -36.28% |
| Return on Capital (ROIC) | -51.45% |
| Revenue Per Employee | 1.30M |
| Profits Per Employee | -3.73M |
| Employee Count | 34 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +85.57% in the last 52 weeks. The beta is 0.71, so IRLAB Therapeutics AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | +85.57% |
| 50-Day Moving Average | 15.12 |
| 200-Day Moving Average | 13.17 |
| Relative Strength Index (RSI) | 40.84 |
| Average Volume (20 Days) | 21,272 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IRLAB Therapeutics AB had revenue of SEK 41.59 million and -119.45 million in losses. Loss per share was -2.30.
| Revenue | 41.59M |
| Gross Profit | -73.91M |
| Operating Income | -129.03M |
| Pretax Income | -119.45M |
| Net Income | -119.45M |
| EBITDA | -127.97M |
| EBIT | -129.03M |
| Loss Per Share | -2.30 |
Balance Sheet
The company has 98.27 million in cash and 55.23 million in debt, giving a net cash position of 43.04 million or 0.83 per share.
| Cash & Cash Equivalents | 98.27M |
| Total Debt | 55.23M |
| Net Cash | 43.04M |
| Net Cash Per Share | 0.83 |
| Equity (Book Value) | 69.69M |
| Book Value Per Share | 1.34 |
| Working Capital | 21.06M |
Cash Flow
| Operating Cash Flow | -108.66M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is -177.74%, with operating and profit margins of -310.28% and -287.25%.
| Gross Margin | -177.74% |
| Operating Margin | -310.28% |
| Pretax Margin | -287.25% |
| Profit Margin | -287.25% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IRLAB Therapeutics AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.13% |
| Shareholder Yield | -0.13% |
| Earnings Yield | -15.99% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 28, 2019. It was a forward split with a ratio of 5.
| Last Split Date | May 28, 2019 |
| Split Type | Forward |
| Split Ratio | 5 |